Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of generic-drug manufacturer Par Pharmaceutical Cos.
So what: Investor excitement can often be a pretty simple recipe. In Par's case, the company posted non-GAAP earnings per share of $0.88, which was well ahead of Wall Street's estimates for the quarter. The quarter was helped by a strong performance from the company's omeprazole sodium bicarbonate capsules -- a generic version of AstraZeneca's
Now what: Overall revenue for the quarter was down 20% from last year and expenses were up as well. Higher gross margins, investment gains, and lower taxes helped drive the improvement in the bottom line. So while the third-quarter results look good against analyst estimates, investors should keep a close eye on how sustainable the company's profit improvements are.
Interested in more info on Par Pharma? Add it to your watchlist by clicking here.